PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCyclophosphamide
Cyclophosphamide
Cyclophosphamide, Cytoxan (cyclophosphamide) is a small molecule pharmaceutical. Cyclophosphamide was first approved as Cytoxan on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, BCR-ABL positive chronic myelogenous leukemia, breast neoplasms, burkitt lymphoma, and endometrial neoplasms amongst others in the USA.
Download report
Favorite
Drugs Approved for Childhood Cancers
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
Show 4 more
Trade Name
FDA
EMA
Cyclophosphamide, Cytoxan (discontinued: Cyclophosphamide, Cytoxan (lyophilized), Neosar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cyclophosphamide
Tradename
Company
Number
Date
Products
CYTOXANBaxterN-012141 RX1982-01-01
2 products, RLD
CYCLOPHOSPHAMIDEBaxterN-217651 RX2023-06-28
2 products, RLD, RS
CYCLOPHOSPHAMIDEDr Reddys LaboratoriesN-212501 RX2020-07-30
3 products, RLD, RS
CYCLOPHOSPHAMIDEDr Reddys LaboratoriesN-210852 RX2023-06-07
3 products, RLD, RS
CYCLOPHOSPHAMIDEEugia Pharma SpecialtiesN-210735 RX2021-08-25
3 products, RLD, RS
CYCLOPHOSPHAMIDEHikma PharmaceuticalsN-203856 RX2013-09-16
2 products, RLD, RS
CYCLOPHOSPHAMIDESandozN-217150 RX2023-09-12
3 products, RLD, RS
Show 4 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cyclophosphamideNew Drug Application2050-01-04
frindovyxNew Drug Application2025-03-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myeloid leukemia acute—D015470C92.0
breast neoplasmsEFO_0003869D001943C50
ovarian neoplasmsEFO_0003893D010051C56
endometrial neoplasmsEFO_0004230D016889—
nephrotic syndromeEFO_0004255D009404N04
multiple sclerosisEFO_0003885D009103G35
lung neoplasms—D008175C34.90
multiple myeloma—D009101C90.0
neuroblastomaEFO_0000621D009447—
precursor cell lymphoblastic leukemia-lymphoma—D054198C91.0
Show 18 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Cyclophosphamide, Cyclophosphamide, Ingenus Pharms Llc
109939522036-02-15DP
Cyclophosphamide, Cyclophosphamide, Eugia Pharma Speclts
96623422035-06-26DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01A: Alkylating agents
— L01AA: Nitrogen mustard analogues
— L01AA01: Cyclophosphamide
HCPCS
Code
Description
C9087
Injection, cyclophosphamide, (auromedics), 10 mg
J8530
Cyclophosphamide; oral, 25 mg
J9070
Cyclophosphamide, 100 mg
Clinical
Clinical Trials
5077 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.941378721223761321
LeukemiaD007938—C9536357914719631003
Breast neoplasmsD001943EFO_0003869C501434742372591886
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0196291771831521
Non-hodgkin lymphomaD008228—C85.920328765730501
Lymphoid leukemiaD007945—C91187279751723496
Multiple myelomaD009101—C90.015125850629441
B-cell lymphomaD016393——19523654719432
Plasma cell neoplasmsD054219——12520448621363
Large b-cell lymphoma diffuseD016403—C83.311421561615358
Show 85 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8026419022—30429
Myeloid leukemia acuteD015470—C92.011317640—17299
Myeloid leukemiaD007951—C9210617535—18287
Hematologic neoplasmsD019337——7110611—17173
MelanomaD008545——90893—3151
CarcinomaD002277—C80.087667—4133
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—279611—8125
SarcomaD012509——525619—8121
Ovarian neoplasmsD010051EFO_0003893C5677576—4120
Myeloproliferative disordersD009196—D47.128814—11115
Show 192 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C254636——367
Liver neoplasmsD008113EFO_1001513C22.03319——343
Stomach neoplasmsD013274EFO_0003897C163917——141
Prostatic neoplasmsD011471—C612911——136
Hepatocellular carcinomaD006528—C22.02518——334
Uterine cervical neoplasmsD002583——2412———28
Skin neoplasmsD012878EFO_0004198C441220———27
Prolymphocytic leukemiaD015463——719——125
MesotheliomaD008654—C452013———23
Esophageal neoplasmsD004938—C15209———21
Show 264 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Female genital neoplasmsD005833——6———17
Adrenocortical carcinomaD018268——3————3
Antiphospholipid syndromeD016736EFO_0002689D68.611———23
Nervous system diseasesD009422—G00-G993————3
PregnancyD011247EFO_0002950Z33.11———12
Juvenile arthritisD001171EFO_1002007M081———12
AnalgesiaD000698——2————2
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A2————2
Immunoglobulin g4-related diseaseD000077733—D89.841———12
Bile duct neoplasmsD001650——2————2
Show 32 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hemoglobin sc diseaseD006450EFO_1001797D57.2————22
Type 1 hyper-igm immunodeficiency syndromeD053307——————22
Hyper-igm immunodeficiency syndromeD053306Orphanet_101088D80.5————22
Cytomegalovirus infectionsD003586EFO_0001062B25————22
Hemoglobin c diseaseD006445—D58.2————11
Taste disordersD013651——————11
DysgeusiaD004408—R43.2————11
AgeusiaD000370EFO_1001758—————11
AtaxiaD001259—R27.0————11
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
Show 52 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCyclophosphamide
INNcyclophosphamide
Description
Cyclophosphamide is a phosphorodiamide that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by two 2-chloroethyl groups at the amino nitrogen atom. It has a role as a carcinogenic agent, an alkylating agent, an immunosuppressive agent, an antineoplastic agent, an antirheumatic drug, an environmental contaminant, a xenobiotic and a drug allergen. It is a phosphorodiamide, a nitrogen mustard and an organochlorine compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O.O=P1(N(CCCl)CCCl)NCCCO1
Identifiers
PDB—
CAS-ID6055-19-2
RxCUI—
ChEMBL IDCHEMBL1200796
ChEBI ID4026
PubChem CID2907
DrugBankDB00531
UNII ID6UXW23996M (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cyclophosphamide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 45,930 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
158,720 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use